Ge Long Hui·2026-01-08 10:32Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Fosun Wanguo, has submitted a drug registration application for a new drug, SAF-189, aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [1] - The new drug is an innovative small molecule chemical drug, with another indication for ROS1-positive NSCLC having completed Phase II clinical trials in mainland China as of the announcement date [1] - As of November 2025, the cumulative R&D investment for this new drug is approximately RMB 480 million (unaudited) [1] Group 2 - According to IQVIA CHPA data, the sales revenue for major drugs treating ALK-positive NSCLC in mainland China is projected to be approximately RMB 3.367 billion in 2024 [1]